{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:39Z","timestamp":1756902159416,"version":"3.44.0"},"reference-count":39,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>Pharmacokinetic parameters can be significantly altered for both extracorporeal life support (ECLS) and continuous renal replacement therapy (CRRT). This case report describes the pharmacokinetics of continuous-infusion meropenem in a patient on ECLS with concurrent CRRT. A 2.8-kg, 10-day-old, full-term neonate born via spontaneous vaginal delivery presented with hypothermia, lethargy, and a ~500-g weight loss from birth. She progressed to respiratory failure on hospital day 2 (HD 2) and developed sepsis, disseminated intravascular coagulation, and liver failure as a result of disseminated adenoviral infection. By HD 6, acute kidney injury was evident, with progressive fluid overload &gt;1500 mL (+) for the admission. On HD 6 venoarterial ECLS was instituted for lung protection and fluid removal. On HD 7 she was initiated on CRRT. On HD 12, a blood culture returned positive and subsequently grew <jats:italic>Pseudomonas aeruginosa<\/jats:italic> with a minimum inhibitory concentration (MIC) for meropenem of 0.25 mg\/L. She was started on vancomycin, meropenem, and amikacin. A meropenem bolus of 40 mg\/kg was given, followed by a continuous infusion of 10 mg\/kg\/hr (240 mg\/kg\/day). On HD 15 (ECLS day 9) a meropenem serum concentration of 21 mcg\/mL was obtained, corresponding to a clearance of 7.9 mL\/kg\/min. Repeat cultures from HDs 13 to 15 (ECLS days 7\u20139) were sterile. This meropenem regimen was successful in providing a target attainment of 100% for serum concentrations above the MIC for \u226540% of the dosing interval and was associated with a sterilization of blood in this complex patient on concurrent ECLS and CRRT circuits.<\/jats:p>","DOI":"10.5863\/1551-6776-21.1.92","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T21:23:41Z","timestamp":1457040221000},"page":"92-97","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: A Case Report"],"prefix":"10.5863","volume":"21","author":[{"given":"Jeffrey J.","family":"Cies","sequence":"first","affiliation":[{"name":"The Center for Pediatric Pharmacotherapy LLC, Pottstown, Pennsylvania"},{"name":"St. Christopher's Hospital for Children, Philadelphia, Pennsylvania"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne S.","family":"Moore","sequence":"additional","affiliation":[{"name":"The Center for Pediatric Pharmacotherapy LLC, Pottstown, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan B.","family":"Conley","sequence":"additional","affiliation":[{"name":"St. Christopher's Hospital for Children, Philadelphia, Pennsylvania"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy J.","family":"Dickerman","sequence":"additional","affiliation":[{"name":"St. Christopher's Hospital for Children, Philadelphia, Pennsylvania"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Small","sequence":"additional","affiliation":[{"name":"St. Christopher's Hospital for Children, Philadelphia, Pennsylvania"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick","family":"Carella","sequence":"additional","affiliation":[{"name":"St. Christopher's Hospital for Children, Philadelphia, Pennsylvania"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Shea","sequence":"additional","affiliation":[{"name":"St. Christopher's Hospital for Children, Philadelphia, Pennsylvania"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Parker","sequence":"additional","affiliation":[{"name":"St. Christopher's Hospital for Children, Philadelphia, Pennsylvania"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Chopra","sequence":"additional","affiliation":[{"name":"The Center for Pediatric Pharmacotherapy LLC, Pottstown, Pennsylvania"},{"name":"NYU Langone Medical Center, New York, New York"},{"name":"NYU School of Medicine, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"key":"i1551-6776-21-1-92-b1","series-title":"Nat Rev Microbiol","first-page":"289","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","year":"2004","unstructured":"Drusano\n              GL.\n            \n          \n          Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019. Nat Rev Microbiol. 2004;2:289\u2013300."},{"key":"i1551-6776-21-1-92-b2","series-title":"Pediatr Infect Dis J","first-page":"168","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children","volume":"33","year":"2014","unstructured":"Cies\n              JJ\n            , ShankarV, SchlichtingC, KutiJL.\n          Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children. Pediatr Infect Dis J. 2014;33:168\u2013173."},{"key":"i1551-6776-21-1-92-b3","unstructured":"Cies\n              JJ\n            , MooreW, ChopraA.\n          Meropenem pharmacokinetics in critically ill children. Society of Critical Care Medicine 43rd Annual Critical Care Congress; January 9\u201313, 2014; San Francisco, CA.","article-title":"Meropenem pharmacokinetics in critically ill children"},{"key":"i1551-6776-21-1-92-b4","series-title":"Anaesth Intensive Care","first-page":"999","article-title":"Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit?: the antibiotic story","volume":"39","year":"2011","unstructured":"Lipman\n              J\n            , UdyAA, RobertsJA.\n          Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit?: the antibiotic story. Anaesth Intensive Care. 2011;39:999\u20131000."},{"key":"i1551-6776-21-1-92-b5","series-title":"Clin Infect Dis","first-page":"1072","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","year":"2014","unstructured":"Roberts\n              JA\n            , PaulSK, AkovaM, \n          et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?Clin Infect Dis. 2014;58:1072\u20131083."},{"key":"i1551-6776-21-1-92-b6","series-title":"Int J Antimicrob Agents","first-page":"455","article-title":"What's behind the failure of emerging antibiotics in the critically ill?: understanding the impact of altered pharmacokinetics and augmented renal clearance","volume":"39","year":"2012","unstructured":"Udy\n              AA\n            , RobertsJA, De WaeleJJ, \n          et al. What's behind the failure of emerging antibiotics in the critically ill?: understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents. 2012;39:455\u2013457."},{"key":"i1551-6776-21-1-92-b7","series-title":"Antimicrob Agents Chemother","first-page":"1139","article-title":"Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation","volume":"40","year":"1996","unstructured":"Amaker\n              RD\n            , DiPiroJT, BhatiaJ.\n          Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996;40:1139\u20131142."},{"key":"i1551-6776-21-1-92-b8","series-title":"Clin Pharmacokinet","first-page":"457","article-title":"Clinical pharmacokinetics during continuous haemofiltration","volume":"26","year":"1994","unstructured":"Bressolle\n              F\n            , KinowskiJM, de la CoussayeJE, \n          et al. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet. 1994;26:457\u2013471."},{"key":"i1551-6776-21-1-92-b9","series-title":"Am J Kidney Dis","first-page":"1019","article-title":"Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis","volume":"31","year":"1998","unstructured":"Joy\n              MS\n            , MatzkeGR, FryeRF, PalevskyPM.\n          Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis. 1998;31:1019\u20131027."},{"key":"i1551-6776-21-1-92-b10","series-title":"Br J Clin Pharmacol","first-page":"265","article-title":"Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation","volume":"60","year":"2005","unstructured":"Mulla\n              H\n            , PooboniS.\n          Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005;60:265\u2013275."},{"key":"i1551-6776-21-1-92-b11","series-title":"Nat Rev Microbiol","first-page":"289","article-title":"Antimicrobial pharmacodynamics: critical interactions of bug and drug","volume":"2","year":"2004","unstructured":"Drusano\n              GL.\n            \n          \n          Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nat Rev Microbiol. 2004;2:289\u2013300."},{"key":"i1551-6776-21-1-92-b12","series-title":"Clin Infect Dis","first-page":"42","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","year":"2003","unstructured":"Drusano\n              GL.\n            \n          \n          Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36:42\u201350."},{"key":"i1551-6776-21-1-92-b13","series-title":"Pharmacotherapy","first-page":"291","article-title":"Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa","volume":"23","year":"2003","unstructured":"Tam\n              VH\n            , LouieA, LomaestroBM, DrusanoGL.\n          Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003;23:291\u2013295."},{"key":"i1551-6776-21-1-92-b14","series-title":"Pharmacotherapy","first-page":"e32","article-title":"Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient","volume":"35","year":"2015","unstructured":"Cies\n              JJ\n            , MooreWSJr, CalamanS, \n          et al. Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient. Pharmacotherapy. 2015;35:e32\u2013e36."},{"key":"i1551-6776-21-1-92-b15","series-title":"Pharmacotherapy","first-page":"e175","article-title":"Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support","volume":"34","year":"2014","unstructured":"Cies\n              JJ\n            , MooreWSJr, DickermanMJ, \n          et al. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support. Pharmacotherapy. 2014;34:e175\u2013e179."},{"key":"i1551-6776-21-1-92-b16","series-title":"Pediatr Blood Cancer","first-page":"379","article-title":"Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population","volume":"53","year":"2009","unstructured":"Courter\n              JD\n            , KutiJL, GirottoJE, NicolauDP.\n          Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009;53:379\u2013385."},{"key":"i1551-6776-21-1-92-b17","series-title":"Clin Infect Dis","first-page":"S42","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","year":"2003","unstructured":"Drusano\n              GL.\n            \n          \n          Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36:S42\u2013S50."},{"key":"i1551-6776-21-1-92-b18","series-title":"Br J Clin Pharmacol","first-page":"259","article-title":"Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration","volume":"58","year":"2004","unstructured":"DelDot\n              ME\n            , LipmanJ, TettSE.\n          Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004;58:259\u2013268."},{"year":"2007","series-title":"Meropenem (Merrem) [package insert]","key":"i1551-6776-21-1-92-b19","unstructured":"Meropenem (Merrem) [package insert]. Wilmington, DE: AstraZeneca; 2007."},{"issue":"3","key":"i1551-6776-21-1-92-b20","series-title":"Drugs","first-page":"653","article-title":"Meropenem: a review of its use in patients in intensive care","volume":"59","year":"2000","unstructured":"Hurst\n              M\n            , LambHM.\n          Meropenem: a review of its use in patients in intensive care. Drugs. 2000;59(3):653\u2013680."},{"issue":"11","key":"i1551-6776-21-1-92-b21","series-title":"J Clin Pharmacol","first-page":"1294","article-title":"Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients","volume":"45","year":"2005","unstructured":"Isla\n              A\n            , MaynarJ, Sanchez-IzquierdoJA, \n          et al. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol. 2005;45(11):1294\u20131304."},{"issue":"9","key":"i1551-6776-21-1-92-b22","series-title":"Antimicrob Agents Chemother","first-page":"2421","article-title":"Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration","volume":"42","year":"1998","unstructured":"Krueger\n              WA\n            , SchroederTH, HutchisonM, \n          et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother. 1998;42(9):2421\u20132424"},{"issue":"12","key":"i1551-6776-21-1-92-b23","series-title":"J Clin Pharmacol","first-page":"1329","article-title":"Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients","volume":"43","year":"2003","unstructured":"Robatel\n              C\n            , DecosterdLA, BiollazJ, \n          et al. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol. 2003;43(12):1329\u20131340."},{"issue":"1","key":"i1551-6776-21-1-92-b24","series-title":"Clin Pharmacol Ther","first-page":"50","article-title":"Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration","volume":"65","year":"1999","unstructured":"Tegeder\n              I\n            , NeumannF, BremerF, \n          et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther. 1999;65(1):50\u201357."},{"issue":"9","key":"i1551-6776-21-1-92-b25","series-title":"Antimicrob Agents Chemother","first-page":"2417","article-title":"Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration","volume":"42","year":"1998","unstructured":"Thalhammer\n              F\n            , SchenkP, BurgmannH, \n          et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1998;42(9):2417\u20132420."},{"issue":"5","key":"i1551-6776-21-1-92-b26","series-title":"J Antimicrob Chemother","first-page":"701","article-title":"Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure","volume":"45","year":"2000","unstructured":"Valtonen\n              M\n            , TiulaE, BackmanJT, NeuvonenPJ.\n          Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2000;45(5):701\u2013704."},{"issue":"10","key":"i1551-6776-21-1-92-b27","series-title":"Crit Care Med","first-page":"3412","article-title":"Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration","volume":"28","year":"2000","unstructured":"Ververs\n              TF\n            , van DijkA, VinksSA, \n          et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med. 2000;28(10):3412\u20133416."},{"issue":"12","key":"i1551-6776-21-1-92-b28","series-title":"J Clin Pharmacol","first-page":"1421","article-title":"Meropenem in children receiving continuous renal replacement therapy: clinical trial simulations using realistic covariates","volume":"54","year":"2014","unstructured":"Nehus\n              EJ\n            , MouksassiS, VinksAA, Gold-steinS.\n          Meropenem in children receiving continuous renal replacement therapy: clinical trial simulations using realistic covariates. J Clin Pharmacol. 2014;54(12):1421\u20131428."},{"key":"i1551-6776-21-1-92-b29","series-title":"Crit Care Med","first-page":"2433","article-title":"Antibiotic resistance\u2013what's dosing got to do with it?","volume":"36","year":"2008","unstructured":"Roberts\n              JA\n            , KrugerP, PatersonDL, LipmanJ.\n          Antibiotic resistance\u2013what's dosing got to do with it?\n          Crit Care Med. 2008;36:2433\u20132440."},{"key":"i1551-6776-21-1-92-b30","series-title":"JAMA","first-page":"1857","article-title":"Resistance to nalidixic acid: a misconception due to under-dosage","volume":"236","year":"1976","unstructured":"Stamey\n              TA\n            , BragonjeJ.\n          Resistance to nalidixic acid: a misconception due to under-dosage. JAMA. 1976;236:1857\u20131860."},{"key":"i1551-6776-21-1-92-b31","series-title":"J Antimicrob Chemother","first-page":"563","article-title":"Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa","volume":"33","year":"1994","unstructured":"Fantin\n              B\n            , FarinottiR, ThabautA, CarbonC.\n          Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother. 1994;33:563\u2013569."},{"key":"i1551-6776-21-1-92-b32","series-title":"Antimicrob Agents Chemother","first-page":"2276","article-title":"beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa","volume":"50","year":"2006","unstructured":"Gugel\n              J\n            , Dos Santos PereiraA, PignatariAC, GalesAC.\n          beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:2276\u20132277."},{"key":"i1551-6776-21-1-92-b33","series-title":"Crit Care Med","first-page":"580","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012","volume":"41","year":"2013","unstructured":"Dellinger\n              RP\n            , LevyMM, RhodesA, \n          et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580\u2013637."},{"key":"i1551-6776-21-1-92-b34","series-title":"Crit Care","first-page":"R206","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams","volume":"15","year":"2011","unstructured":"Goncalves-Pereira\n              J\n            , PovoaP.\n          Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care. 2011;15:R206."},{"key":"i1551-6776-21-1-92-b35","series-title":"Am J Med","first-page":"529","article-title":"Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis","volume":"115","year":"2003","unstructured":"Harbarth\n              S\n            , GarbinoJ, PuginJ, \n          et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529\u2013535."},{"key":"i1551-6776-21-1-92-b36","series-title":"Chest","first-page":"462","article-title":"Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients","volume":"115","year":"1999","unstructured":"Kollef\n              MH\n            , ShermanG, WardS, FraserVJ.\n          Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462\u2013474."},{"key":"i1551-6776-21-1-92-b37","series-title":"Crit Care Med","first-page":"1589","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","year":"2006","unstructured":"Kumar\n              A\n            , RobertsD, WoodKE, \n          et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589\u20131596."},{"key":"i1551-6776-21-1-92-b38","series-title":"Clin Infect Dis","first-page":"284","article-title":"Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial","volume":"38","year":"2004","unstructured":"MacArthur\n              RD\n            , MillerM, AlbertsonT, \n          et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004;38:284\u2013288."},{"key":"i1551-6776-21-1-92-b39","series-title":"Pediatr Infect Dis J","first-page":"295","article-title":"Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children","volume":"30","year":"2011","unstructured":"Muszynski\n              JA\n            , KnatzNL, SargelCL, \n          et al. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J. 2011;30:295\u2013301."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/21\/1\/article-p92.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/21\/1\/92\/1786687\/1551-6776-21_1_92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/21\/1\/article-p92.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/21\/1\/article-p92.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:39:48Z","timestamp":1747355988000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/21\/1\/article-p92.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":39,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-21.1.92","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2016]]}}}